Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARI0002h CAR-T for Relapsed/Refractory Multiple Myeloma
2024-515650-24-00Phase 2Completed
- Sponsor
- IDIBAPS
- Start
- Jul 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ARI0002h in multiple myeloma (MM), sponsored by IDIBAPS. Started Jul 2024; status: completed.
02
Drugs
ARI0002h
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-515650-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515650-24-00.